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Objectives: To assess whether applying the 2010 ACR/EULAR Classification 
Criteria for rheumatoid arthritis (RA) to primary care referrals improved triage 
decisions and reduced waiting times; and to determine the sensitivity and specificity 
of this strategy. 
Methods: The 2010 ACR/EULAR Classification Criteria for RA were prospectively 
applied over 8 months to all new adult rheumatology referrals with possible 
inflammatory arthritis. If the referral contained insufficient information, a request was 
sent for more information. Joint count was based on GP report and definite swelling 
was not required. Referrals meeting triage criteria were offered an appointment 
within 6 weeks. Data was collected on rheumatologist diagnosis, DMARD use and 
waiting times.  
Results: Of 457 referrals screened, 180 met inclusion and exclusion criteria, and 
143 had sufficient data after requests for information. Seventy-one referrals met 
triage criteria, and of the 63 attending the appointment, 25 (40%) received a 
rheumatologist diagnosis of RA. Seventy-two referrals did not meet criteria, and 1/49 
attending (2%) had RA. The characteristics of the tool for a diagnosis of RA were: 
sensitivity 96%, specificity 56%, positive predictive value 40%, and negative 
predictive value 98%. Median wait times for referrals fulfilling and not fulfilling triage 
tool criteria were 7.9 weeks and 45.4 weeks respectively.   
Conclusion: Implementing the 2010 ACR/EULAR Classification Criteria for RA as a 
prioritisation tool for primary care referrals improved the yield of patients 
subsequently diagnosed with RA. Waiting time was reduced for RA patients. 
Applying this strategy in areas of rheumatologist scarcity may permit earlier DMARD 
treatment. 
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Significance and Innovations: 
 
• This study innovatively applies the 2010 ACR/EULAR Classification Criteria 
for RA in a novel application - guiding triage decisions for referrals to 
rheumatologists.  
• This triage approach has the capacity to detect new RA cases with a high 




The early treatment of rheumatoid arthritis (RA) with disease modifying anti-
rheumatic drugs (DMARDs) leads to improved disease activity and reduced 
radiographic damage, 1,2 and early RA treatment should be given a high priority.  In 
many countries there is an overall shortage and an uneven distribution of 
rheumatologists, which can lead to long delays in accessing specialist care3. For 
example, at a regional Australian health service in June 2011, the number of newly 
referred patients waiting for an appointment with the solitary rheumatologist was 
1113, with waiting times of over a year for inflammatory arthritis patients categorised 
as urgent4.  
 
Best practice recommends that patients with early inflammatory arthritis be seen by 
a rheumatologist within 6 weeks of symptom onset5.  Even with an adequate supply 
of rheumatologists, many early arthritis patients are not seen in this timeframe6.  The 
problem is much worse in areas of specialist scarcity, where average waiting times 
can be months to years. In this setting a systematic triage approach is needed which 
rations care and gives priority access to patients with more severe, treatable, or 
time-dependent conditions.   
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A recent literature review7 summarised some of the strategies that have been used 
to reduce delays at any of four steps (1. from symptom onset to assessment in 
primary care; 2. from primary care to rheumatology referral; 3. from rheumatology 
referral to assessment; and 4. from rheumatology assessment to DMARD 
commencement), and we are primarily interested in reducing the delay at point 
three.  One study applied a rheumatology triage method used a 5 tier triage grading 
system (A+ to D) to triage referrals.8  The sensitivity of this technique for detecting 
truly urgent cases upon rheumatology review was only 59%, and this low sensitivity 
was thought to be influenced by the poor quality of referral information. Another 
approach used a non-diagnosis dependent priority referral scoring system9 but has 
not yet been tested to show if it improves waiting times.  Tavares et al10 used a 
patient self-administered tool to detect inflammatory arthritis amongst all patients 
referred to rheumatology clinic, and the final model gave a sensitivity of 85.5% and 
specificity of 87.3%. The predictive elements were: younger age, male sex, trouble 
making a fist, morning stiffness, ever told you have RA, and diagnosis of psoriasis. 
Barbour11 used an 8 point score administered by a nurse, and found that a score of 
3 or more gave a sensitivity of 97% and specificity of 55% for inflammatory joint 
disease, however this tool required the nurse to asses the patient for synovitis on the 
day of consultant review, and as such was not used to allocate urgency of 
appointments.  
 
One difficulty in applying rheumatology triage is the lack of information provided by 
primary care providers.8,12 To combat this, a rheumatology specific referral form can 
be used which the primary care provider completes with the initial referral. This 
improves the completeness of referral information13.  
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In 2010, the ACR and EULAR jointly published new classification criteria14 aiming to 
improve detection of early RA. These criteria showed high sensitivity for 
methotrexate prescription at one year in each of the three validation cohorts (namely 
97%, 91% and 87%). In this study we employ these criteria in a novel application as 
a triage tool. We test whether using these four variables (joint count, serology, 
inflammatory markers and symptom duration) can successfully prioritise new arthritis 
referrals from a community medical practitioner to a tertiary referral rheumatology 
service. We describe the sensitivity and specificity of this intervention, and its impact 
on the waiting time for accessing specialist care for people with RA. 
 
Methods: 
For 8 months from April 2011, consecutive new referrals to the Townsville Hospital 
Rheumatology clinic of adults with possible inflammatory arthritis were prospectively 
assessed. Inclusion required that the referral was predominantly for a joint problem.  
Exclusion criteria were: previous diagnosis by a rheumatologist, age less than 18 
years, back pain alone, and absence of joint swelling explicitly specified. Each 
referral was scored using the 2010 ACR/EULAR Classification Criteria for RA (Table 
1), modified as follows: ‘definite swelling’ was not required in the referral; ‘synovitis 
not better explained by another disease’ was not required; and joint count was 
based on referring doctor’s report of involved joints. If insufficient information for 
scoring was provided in the referral, a request was sent to the referring doctor to 
supply the additional information. This arrangement had been previously discussed 
with the local Division of General Practitioners. Patients were given an appointment 
at approximately 6 weeks if they met the criteria (scoring 6 or more), or a routine 
appointment if they did not. Following the initial rheumatologist consultation these 
data were collected for each patient: the rheumatologist’s diagnosis, actual fulfilment 
of 2010 RA criteria, DMARD prescription, RF & CCP status and waiting times from 
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referral to consultation. In cases where the diagnosis was unclear at the initial 
appointment, the diagnosis at the second appointment was used. The Chi-Squared 
Test was used for comparisons of categorical data and the Mann-Whitney U test 
was used for comparisons of continuous non-parametric variables. Ethics approval 




A total of 457 consecutive referrals were screened (Figure 1). Scoring was applied to 
143 referrals, of which 71 (50%) met scoring criteria (Group 1), with the remaining 
72 forming Group 2.  The usual triage process (categorising referrals as 1, 2 or 3), 
was applied concurrently, and 87% of all referrals were Category 1. From Group 1, 
63 (89%) attended their appointment, and 25 (40%) were diagnosed with RA. In 
Group 2, 49 patients (68%) attended their appointment, and 1 person (2%) was 
diagnosed with RA. Eighty-one referrals were sent back to the referring doctor 
requesting further information. Of these, 37 (46% of requests, or 21% of 180 
relevant referrals) were not returned and were lost to the study. Mean ages were 56 
and 49 years and female sex was 70% and 73%, in groups 1 and 2 respectively 
(Table 2).  
 
Relative frequencies of rheumatologic diagnoses were differentially distributed within 
the two triage groups (Figure 2). RA was the most common diagnosis in Group 1, 
followed by osteoarthritis (OA). In Group 2, RA was rare; the most common 
diagnoses were osteoarthritis, psoriatic arthritis and fibromyalgia (FM). No diagnosis 
was able to be made in one patient from Group 1 and two patients from Group 2. 
DMARD use after rheumatologist assessment is shown in Table 2. The majority of 
DMARD use in Group 2 was for psoriatic arthritis or other inflammatory arthritides.   
Page 6 of 19
John Wiley & Sons, Inc.
Arthritis Care & Research
 7
 
This triage tool was 96% sensitive for a diagnosis of RA. Specificity was 56%. 
Positive predictive value was 40% and negative predictive value 98%. The overall 
prevalence of RA in the patients assessed was 23%.  Results of only applying 
seropositivity as a predictor of RA are shown in Table 3. Where only one of RF or 
CCP was available, this data was used for seropositivity; RF was missing in 5 and 
anti-CCP in 19.  
 
Of the patients who were ultimately diagnosed as having RA, 96% had been offered 
the early appointment and one patient (4%) the usual appointment. Of those not 
diagnosed as having RA, 38/86 (44%) had been offered the early appointment, and 
56% the usual appointment.  Waiting times were significantly reduced for patients 
with RA (Figure 3). RA patients had a median wait time of 7.4 weeks and a third 
quartile wait time of 8.8 weeks, compared with 14.4 weeks and 48.3 weeks 
respectively for the non-RA patients.  
 
Discussion: 
We used a novel triage strategy, applying the 2010 ACR/EULAR Rheumatoid 
Arthritis Classification Criteria to primary care referrals. This approach proved highly 
sensitive (96%) for a rheumatologist diagnosis of RA, and also significantly reduced 
waiting times for RA patients. The high sensitivity came at the price of a moderate 
specificity of 56%, which is nevertheless reasonable for a screening tool.  Our tool, 
which can be applied to referrals directly and in some cases requires a request for 
further information, had a sensitivity higher than that of the patient administered tool 
developed by Taveres10 which was 86% sensitive. However the Taveras tool had a 
higher specificity of 87%. Our tool had a similar sensitivity and specificity to the 
nurse administered tool which requires the nurse to assess for synovitis11, which had 
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a sensitivity of 97% and specificity of 55%. In our study, the triage tool was shown to 
be more sensitive than seropositivity alone (tool 96% sensitive vs 89% for 
seropositivity), although less specific (tool 56% specific vs 77% for seropositivity).  
Seropositivity is more specific in assessing referrals for RA, however our triage tool 
identifies more RA patients, which is desirable for a screening tool.  
 
The sensitivity of the triage approach was assisted by an inclusive strategy, such as 
not requiring swelling to be definitely present in the referral. This information was 
often not supplied by the referring doctor, and the reliability of the detection of 
synovitis by non-rheumatologist doctors was likely to be low. This also helped to 
minimise the number of referrals being sent back, which reduces the potential for 
lost cases. Because swelling wasn’t required, the tool may be more broadly 
applicable to referrals from a wider group of practitioners including nurse specialists, 
physician’s assistants, and allied health practitioners, although this wasn’t tested in 
this study. The tool was able to more accurately identify RA cases than the usual 
triage process and would be ideally suited to vetting referrals for entry into an early 
arthritis clinic.   
 
An advantage of this triage tool is that expert knowledge is not required to administer 
it, as it could be scored by anyone trained in applying the tool. In this study the tool 
was applied by a rheumatology registrar, but it could be applied by a nurse or by the 
person who usually triages referrals at a centre. The tool is generally quick to 
complete, as it requires information on just four parameters (joint count, 
seropositivity, inflammatory markers and duration). The request for more information 
can be sent back to the referrer by administrative staff, without imposing a time 
burden on the rheumatologist.  
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Receiving further information from the referrer did prove useful in triaging referrals. 
In one example, a referral for “chronic polyarthralgia...nil significant findings” proved 
to be CCP-positive when additional testing was requested from the referring doctor, 
and the patient was subsequently diagnosed with RA by the rheumatologist.  Of 180 
relevant referrals, 45% did not have sufficient information, and in only 54% of these 
cases was more information supplied. As per the policy of the Hospital, referrals with 
insufficient information were not offered an appointment, such that 21% of 180 
relevant referrals were lost to follow up. If this tool was applied to rheumatology 
practice, cases without the extra information sent back could still be offered a non-
urgent appointment, helping to minimize the potential for missed cases. 
 
Whilst this tool’s sensitivity was high, one case of RA was missed. The referral for 
this case scored 5 on the triage tool (just below cut-off), including 2 points for joint 
count (wrist, knee, ankle and shoulder involved), 2 points for serology (low-titre 
rheumatoid factor, which subsequently became strongly positive), 1 for acute phase 
reactants and 0 for duration. A modification to the approach such as requesting the 
referring doctor to reassess all patients referred but not yet seen every 3-6 months 
with repeat joint assessment and serology might perhaps overcome this problem, 
and improve the sensitivity of the triage tool further. 
 
The triage tool was unable to be applied to 37 referrals (21% of 180 relevant 
referrals) due to lack of information, despite requesting the required information from 
the referrer. This limits the applicability of the data. The true sensitivity and 
specificity of the tool may have been found to be not as high as that reported above, 
had it been possible to apply the triage criteria to all referrals. A further potential 
limitation of this study relates to incomplete attendance at the rheumatology clinic, 
particularly in Group 2 (68% attendance). This loss-to-follow-up of Group 2 was 
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presumably influenced by the much longer waiting times for an appointment in this 
group, and possibly the lack of severity or self-limiting nature of the problem for 
which they were referred. A sensitivity analysis showed that if an additional 6 
patients who were not followed up in Group 2 actually had RA then the sensitivity 
would fall below 80%. However, we feel that this is unlikely; the next available 
rheumatology service was more than 4 hours drive away, meaning that any person 
with a persistent disease such as RA would be likely to attend the local 
rheumatology service once an appointment was offered. Patients permanently 
relocating out of the region were not able to be assessed.  
 
This tool is aimed at identifying patients with an inflammatory arthritis and is not 
applicable to referrals without a primary joint problem, such as (non-articular) SLE or 
giant cell arteritis. This tool is intended to optimize the early diagnosis and treatment 
of RA and would ideally suit screening into an early inflammatory arthritis clinic. 
Concurrent triage processes are needed to triage for rheumatic diseases outside of 
inflammatory and non-inflammatory arthritis. A risk of using this tool in isolation is 
that other potentially life threatening rheumatic diseases could be missed or there 
might be delays in referral. In this study, of 457 referrals screened, 277 did not meet 
inclusion/exclusion criteria and were triaged through a standard three-tier category 
system (Categories 1/2/3). Any referrals deemed to be very urgent (such as possible 
sight-threatening giant cell arteritis or systemic sclerosis with digital ischemia) were 
seen in an emergency rheumatology clinic.  
 
Triage decisions were overall improved with this tool. The usual triage process 
resulted in 87% of referrals being in Category 1 (urgent), which captured all eventual 
diagnoses of RA in the patients who attended. The novel triage process resulted in 
50% of referrals being categorised in Group 1, which captured all but one of the RA 
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patients who attended. This resulted in far fewer patients needing the most urgent 
appointment, whilst still maintaining an excellent pick-up rate for RA. This triage tool 
identified the vast majority of RA patients and offered them an early appointment, 
while the majority of non-RA patients were offered the usual appointment. This triage 
approach achieved better targeted identification of RA patients, and was able to 
produce much improved wait times, as three quarters of RA patients were seen by 
8.8 weeks, whereas three quarters of non-RA patients were seen by just under a 
year (48 weeks). 
 
This triage tool facilitates awareness of the 2010 ACR/EULAR RA criteria amongst 
primary care providers, general physicians or other referrers. The newer criteria shift 
the focus away from markers of long-standing disease or damage (such as erosions 
and rheumatoid nodules, present in the 1987 ACR criteria), towards an earlier 
classification of RA, at the time of presentation with swollen joints. In locations with 
scarce rheumatologist resources, this triage tool offers the potential to increase the 
early introduction of DMARDs in the RA population, and presumably to prevent a 




The systematic application of the 2010 ACR/EULAR Rheumatoid Arthritis 
Classification Criteria as a prioritization tool for new primary care referrals was 96% 
sensitive and 56% specific for a rheumatologist diagnosis of RA. The positive and 
negative predictive values were 40% and 98% respectively. Waiting time was 
significantly reduced for RA patients. In areas of rheumatologist scarcity, this tool 
offers the potential to decrease the future burden of RA disease. 
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Table 1: Triage Scoring System  
from 2010 ACR/EULAR RA Criteria 
 Points 
A. Joint Count  
 1 large joint 0 
2-10 large joints 1 
1-3 small joints* (with or without large joints) 2 
4-10 small joints* (with or without large joints) 3 
>10 joints including at least one small joint* 5 
B. Serology  
Negative RF and CCP 0 
Low +ve RF or CCP (≤3x ULN) 2 
High +ve RF or CCP (>3x ULN) 3 
C. Acute Phase Reactant   
Normal CRP and ESR 0 
Abnormal CRP or ESR 1 
D. Duration  
<6 weeks 0 
≥6 weeks 1 
Add totals for sections A-D.  ≥ 6 meets criteria; <6 does not 
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Table 2: Patient Characteristics and Diagnosis 
 Group 1           
(meeting criteria)   
n=63 




Age (mean, in 
years) 
56 49  
Female sex 44 (70%) 36 (73%) Not sig 
Indigenous 3 (5%) 3 (6%) Not sig 
Seropositive 39 (62%) 4 (8%) p<0.001 (Chi-
square) 
Rheumatologist 
diagnosis of RA 
25 (40%) 1 (2%) p<0.001 (Chi-
square) 
Actually meeting 
2010 RA criteria 
25 (40%) 1 (2%) p<0.001 (Chi-
square) 
MTX use 17 (27%) 7 (14%) Not sig 
DMARD use 26 (41%) 11 (22%)  
DMARD or 
prednisone use 
28 (44%) 18 (37%)  
Waiting time 
(median) 
7.9 weeks 45.4 weeks p<0.001 (Mann-
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Table 3: Predictive Utility of Triage Criteria and of Seropositivity for Diagnosis 
of RA 
 Triage Criteria 
(n=112) 
Seropositivity  





Sensitivity 96.2% 88.5% 70.8% 
Specificity 55.8% 76.7% 100% 
PPV 39.7% 53.5% 100% 
NPV 98.0% 95.7% 90.8% 
 







Page 16 of 19
John Wiley & Sons, Inc.
Arthritis Care & Research
 
 







457 referrals screened  
180 referrals meeting 
inclusions/exclusions 
143 referrals included in study 
277 not meeting study 
inclusion/exclusion criteria 
99 referrals with 
sufficient information 
81 referrals with 
insufficient information  
37 no further info received 
44 further information received 
71 Referrals met triage score 
(Group 1, early appt) 
72 Referrals did not meet triage 
score (Group 2, usual appt) 
49 pts assessed (68% attendance)  63 pts assessed (89% attendance)  
8 pts did not attend appt 
25/63 (40%) diagnosed with RA 1/49 (2%) diagnosed with RA 
23 pts did not attend  
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Median = 7.4 
weeks 
Median = 14.4 
weeks 
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